ReviewFrontiers in cellular and infection microbiology2026
Epigenetic regulation of post-stroke cognitive impairment by gut microbiota and their metabolites.
Review in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-stroke cognitive impairment (PSCI) is a common and disabling complication after stroke, yet its underlying mechanisms remain incompletely understood. Emerging evidence indicates that gut microbiota (GM) and their metabolites play a critical role in the pathogenesis of PSCI through the microbiota-gut-brain (MGB) axis. Increasing studies have demonstrated that GM dysbiosis after stroke leads to alterations in microbial metabolites, including short-chain fatty acids (SCFAs), B vitamins, tryptophan metabolites, bile acids, and other neuroactive compounds, which can influence neuroinflammation, blood-brain barrier integrity, synaptic plasticity, and neuronal survival. Notably, many of these metabolites participate in epigenetic regulation, such as DNA methylation, histone modification, non-coding RNA regulation, chromatin remodeling and RNA modifications, thereby affecting gene expression related to cognitive function and neural repair. This review summarizes recent advances in the relationship between gut microbiota, microbial metabolites, and epigenetic mechanisms in PSCI, and discusses how microbiota-derived metabolites mediate epigenetic reprogramming involved in neuroinflammation, oxidative stress, and neuronal apoptosis. Furthermore, this review highlights potential therapeutic strategies targeting the gut microbiota and their metabolites, including microbiota modulation, metabolite supplementation, and epigenetic intervention. Understanding the interaction between gut microbiota-derived metabolites and epigenetic regulation may provide new insights into the pathogenesis and treatment of PSCI and support the development of personalized therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.